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There are few and conﬂicting studies on the optimal
timing of initial cranial radiation in the treatment of
glioblastoma multiforme (GBM) but none of them
have addressed this issue in the elderly population. We
used the linked Surveillance, Epidemiology, and End
Results (SEER) Medicare database to investigate
whether the time interval from surgery to initiation of
radiation is a signiﬁcant prognostic factor for survival
in subjects aged 65 years with newly diagnosed
GBM. Cox modeling was used to assess the effect of
waiting time on overall survival. We identiﬁed a total
of 1,375 patients, 296 with biopsies and 1,079 with
resections. The median time to the initiation of radio-
therapy was 15 days post operation (interquartile
range 12–21). In the univariate Cox analysis of those
who had debulking surgeries, a waiting time of >22
days showed a signiﬁcant inverse relationship with survi-
val (hazard ratio [HR] 5 0.82, 95% CI 0.70–0.97, p 5
0.02), but after adjustment for confounders, it was not a
statistically signiﬁcant factor in the ﬁnal Cox model
(HR 5 0.99, 95% CI 0.97–1.01, p 5 0.14). Therefore,
waiting time was not a signiﬁcant prognostic factor for
subjects with biopsies in both the univariate and multi-
variate analyses. Although effort should be made to
initiate radiotherapy as soon as possible after surgical
resection/biopsy, a brief delay similar to that
experienced by our cohort does not have a signiﬁcant
impact on survival.
Keywords: elderly, glioblastoma multiforme, SEER–
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A
recent randomized controlled trial (RCT) estab-
lished the efﬁcacy of cranial radiation for newly
diagnosed glioblastoma multiforme (GBM) in
elderly patients aged more than 70.
1 However, there is
a paucity of studies on the appropriate timing of
upfront radiation. Because of the aggressive nature of
GBM, radiotherapy is often recommended to start
approximately 2 weeks following surgery, but at some
centers it was delayed more than 4 weeks post-
operatively. For example, in one RCT comparing an
abbreviated versus a full course of cranial radiation in
elderly patients with GBM, the median time from diag-
nosis to the initiation of radiation was 33 days,
2 and in
another RCT involving radiotherapy for glioblastoma,
the median time was 5.3 weeks.
1 Many factors
may affect the timing of radiation. Referral delay to a
radiation oncologist, resource and stafﬁng constraints,
postoperative complications, time involved in seeking
second opinions, and missed appointments are some of
the factors that may result in the postponement of
radiation.
A mathematical model that was developed to assess
the effect of protracted waiting time found a mean
tumor doubling time of 24 days, and thus a short
delay would be expected to have an adverse effect on
survival.
3 Moreover, the model suggested that no
patients could survive long-term after a 70-day delay.
Although this study raises the theoretical concern that
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able effect on outcome, results among the three retro-
spective studies that addressed this issue have been
conﬂicting, and none of them speciﬁcally evaluated it
in the elderly population, for which the prognosis is
worse than adult GBM.
4 One analysis of 172 patients
in a single hospital showed that every additional week
(after a post-operative period of 2 weeks) of delay
increased the risk of death by 8.9%.
5 In contrast, an
abstract published by the RTOG suggested that GBM
patients who were irradiated beyond 4 weeks had a
signiﬁcant survival advantage over those who began
radiation within 2 weeks of surgery.
6 The third study
on 179 malignant glioma patients found that the
waiting time from surgery to radiotherapy had no
impact on survival.
7
Although an RCT is the best way to resolve these con-
ﬂicting ﬁndings, ethical issues and barriers in conducting
a trial targeted at elderly subjects would render such an
attempt impossible.
8 A representative population-based
study is thus the most feasible method to resolve the
issue of radiation timing in elderly patients with GBM.
In this study, we used Medicare data from 1991 to
2002, linked to the Surveillance, Epidemiology, and
End Results (SEER) cancer registries, to evaluate
whether the time interval from surgery to the initiation
of radiation is an important determinant for survival.
An additional advantage of using the SEER–Medicare
linked ﬁles from this time period is that the effect attrib-
uted to upfront radiotherapy will be unlikely con-
founded by concomitant temozolomide, as combined
chemoradiation in the treatment of newly diagnosed




We used the merged SEER–Medicare database for
patients aged 65 or older who were diagnosed with
GBM from 1991 to 2002 in 13 SEER areas: Atlanta,
Connecticut, Detroit, Hawaii, Iowa, New Mexico,
San Francisco–Oakland, Seattle–Puget Sound, Utah,
Los Angeles, San Jose-Monterey, Rural Georgia, and
the Alaska Native Tumor Registry. These areas cover
approximately 14% of the US population. The registries
ascertain all newly diagnosed GBM cases from multiple
reporting sources. Information derived from SEER
includes GBM histological subtypes, tumor location in
the brain, tumor size, age, sex, self-reported ethnicity,
types of surgery, and survival information.
The Medicare program and database are maintained
by the Health Care Finance Administration (HCFA),
which covers hospital, physician, and other medical ser-
vices for more than 97% of people aged 65 years.
These data were available for all beneﬁciaries starting
in 1991, and their claims are available through 2003.
A previous study of persons aged 65 years appearing
in the SEER registries established that Medicare eligi-
bility could be veriﬁed for 94% of cases.
9 In this study,
we retrieved information related to socioeconomic
status (SES), treatment hospital location (metropolitan
versus nonmetropolitan), comorbidities, surgery dates,
the timing of radiation, and chemotherapies from
Medicare ﬁles (see details below).
The Selection of the Study Population
In the linked SEER–Medicare database from January
1991 to December 2002, weidentiﬁed2,018 newlydiag-
nosed GBM subjects (age 65). To ensure that we have
access to subjects’ complete medical records, which are
represented by billed items in Medicareﬁles, weincluded
only those who had both Medicare Parts A and B and
were not enrolled in a health maintenance organization
(HMO) during the period from 12 months before
through 12 months after diagnosis. Subjects had no
prior history of other malignancies. We excluded (1)
subjects who did not have pathological conﬁrmation
(n ¼ 148); (2) subjects who never got cranial radiation
(n ¼ 289); (3) those who did not initiate radiation
within 90 days of surgery (n ¼ 45); and (4) subjects
who died within 90 days of diagnosis (n ¼ 161). The
exclusion of the last group was necessary as they might
have died prior to completing upfront radiotherapy for
a variety of unrelated reasons, and thus their inclusion
could bias our survival estimates attributed to cranial
radiation. Of the 161 patients who died within 90
days, 134 (83.2%) passed away within 30 days of diag-
nosis. Furthermore, we included only cases that started
radiotherapy within 90 days of surgery, as the database
does not allow us to ascertain whether radiation
initiated beyond this period might have been indicated
for recurrent disease. Therefore, we excluded a total of
643 of 2,018 subjects; the remaining 1,375 patients,
296 with biopsies and 1,079 with surgical resections,
formed our study cohort.
Measurement of the Timing of Initiation of Upfront
Cranial Radiation
The receipt and timing of cranial radiation after surgery
were ascertained using Medicare ﬁles, using Current
Procedural Terminology, Fourth Edition (CPT-4),
codes for treatment (77403, 77413, 77417, 77418,
and 77427).
We determined the time interval from surgery to
cranial radiation (in days) using the start date of radi-
ation subtracted by the last date of the surgical pro-
cedure (biopsy or craniotomy for surgical resection).
For regression analyses, we categorized the variable
time from surgery to radiation into quartiles based on
the distribution of this variable.
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Measurements and Survival Estimates
The types of surgery were determined by SEER, and the
surgical dates were conﬁrmed by CPT-4. Surgery was
classiﬁed as biopsy-only, subtotal resection, gross total
resection, and natural oriﬁce surgery if the degree of
resection was not speciﬁed. We used the last surgical
date if more than one surgery was performed.
Adjuvant chemotherapyexposures, eitherafter radiation
or at recurrence, were ascertained from Medicare ﬁles
using codes for ICD-9-CM diagnosis (V581, V662),
HCPCS (Q0083, Q0084, J9000–J9999), and CPT
(96401–96450; 96522–96549).
According to a method developed by Krieger,
10 we
generated an aggregate SES score by incorporating a
hierarchy of income data from the 2000 census. The
method was based on a formula that integrates census
tract median income, ZIP code median income, census
per-capita income, and ZIP code per-capita income.
Patients were ranked on a 1–5 scale, with 1 as the
lowest and 5 the highest values. Patients for whom all
of these values were missing were assigned to the
lowest SES category.
To assess the prevalence of comorbid disease in our
cohort, we used the Klabunde adaptation of the
Charlson comorbidity index.
11,12 All relevant ICD-9
diagnosis codes, ICD-9 procedure codes, and HCPCS
procedure codes within hospital and physician claim
ﬁles were searched to identify selected comorbidities
from 365 days before to 120 days after diagnosis of
cancer. Each category was weighted based on the
Charlson index.
We measured the overall survival time in months as
the interval from the date of GBM diagnosis to the
Medicare date of death. Our data set provided follow-up
through December 31, 2003. Those who survived past
this time were censored. As GBM is rapidly fatal, and
we excluded those who were diagnosed with other
cancers prior to their GBM diagnoses, it would be
uncommon that the cause of death was due to reasons
unrelated to GBM.
Statistical Analyses
The demographic and clinical characteristics of our
cohort were illustrated by frequency and percentage.
As the variable time from surgery to radiation was cate-
gorized in quartiles, its associations with other clinical
variables were determined using ordinal logistic
regression.
In Cox proportional hazard (PH) modeling, prognos-
tic variables were ﬁrst assessed using univariate analyses.
Those variables that achieved a p-value of 0.25 were
included in a multivariable model, which began with
all potential covariates. Backward elimination was
used to remove covariates with p . 0.05. This process
was continued until covariates kept in the model were
all signiﬁcant. A preliminary main effect model was
used after this stage. Subsequently, those variables that
were not initially selected for model building (p-values
of univariate analyses .0.25) were added back into
the preliminary main effect model. This process would
identify those covariates that were not signiﬁcantly
related to survival by themselves but could make an
important contribution in the presence of other vari-
ables. Meaningful interaction terms based on prior
knowledge were introduced one by one into the prelimi-
nary main effect model, and each was kept if p , 0.05.
They were deﬁned a priori as interactions between age
and radiation, age and surgery, race and radiation, and
race and surgery. After the derivation of the full model
(main effect model plus interaction terms), PH assump-
tion was tested by plotting Schoenfeld residuals against
time for each covariate. Afterward, proportion hazard
assumption tests based on the technique of Grambsch
and Therneau were conducted globally as well as for
each individual variable.
13 STATA (version 9.2,
College Station, TX, USA) was used for all analyses.
Results
Table 1 shows the socio-demographic and clinical
characteristics of our entire study cohort, and separately
for those who had surgical resections and biopsies. The
median age of the entire study cohort was 72. More
than 90% of the patients were Caucasian and resided
in central and peripheral counties of metropolitan
areas with populations greater than 250,000. Of the
1,375 subjects overall, 77% (1,079 patients) had a
debulking surgery. Of the 1079 patients who had
tumor resection, 53.2% had a gross total resection,
44.9% had a subtotal resection, and 1.9% had nonspe-
ciﬁed resection. More than 1 in 4 patients received some
form of intravenous chemotherapy. Because of the com-
plexity in localizing these tumors, the variable tumor
location provided only the broad regions or lobes of
the primary lesions. Moreover, the variable tumor size
was missing in more than 35% of patients; thus,
because of imprecise characterization, these two clinical
factors were not included in subsequent regression
analyses.
The median survival of those who had a gross total
resection was 9.3 months, subtotal resection 8.0
months, surgery NOS 6.7 months, and biopsy 5.6
months. For the entire cohort, the median time to the
initiation of radiation was 15 days (interquartile range
[IQR] 12–22 days). For the group that had tumor resec-
tions, the median time to radiation was 16 days (IQR
12–22 days), whereas in those who had biopsies, the
median was 10 days (IQR 6–16 days). The 95th percen-
tile of those with biopsies was 37 days, and with tumor
resections was 40 days. Therefore, to categorize the vari-
able time interval to radiation, we divided it into quar-
tiles: 0–12 days (reference), 13–16, 17–22, and 23
days. Since the sample size of the biopsy group was
small, we dichotomized only the variable at its median
(10 or .10 days).
Ordinal logistic regression revealed that only the
types of surgery were associated with the timing of radi-
ation (Table 2). When compared to biopsy subjects,
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Clinical and Demographic
Factors
Frequency (%) for the Entire
Cohort, n 5 1375
Frequency (%) for those with
Craniotomy, n 5 1079
Frequency (%) for those with
Biopsy, n 5 296
Age at diagnosis
65–69 398 (29.0) 318 (29.5) 80 (27.0)
70–74 482 (35.1) 385 (35.7) 97 (32.8)
75–79 336 (24.4) 254 (23.5) 82 (27.7)
80 or above 159 (11.6) 122 (11.3) 37 (12.5)
GBM histological subtypes
Classical GBM 1331 (96.8) 1038 (96.2) 293 (99.0)
Giant cell GBM 11 (0.80) 9 (0.83) ,5( ,1.7)
a
Gliosarcoma 33 (2.40) 32 (3.0) ,5( ,1.7)
a
Racial groups
Caucasian 1270 (92.4) 1002 (92.9) 268 (90.5)
African American 35 (2.6) 22 (2.0) 13 (4.4)
Hispanic 17 (1.2) 16 (1.5) ,5( ,1.7)
a
Other racial group 53 (3.9) 39 (3.6) 14 (4.7)
Residence in metropolitan areas 1245 (90.6) 972 (90.1) 273 (92.2)
Socio-economic status
Lowest quintile 274 (19.9) 207 (19.2) 65 (22.0)
Second quintile 266 (19.4) 232 (21.5) 54 (18.2)
Third quintile 277 (20.2) 212 (19.7) 65 (22.0)
Fourth quintile 286 (20.8) 203 (18.8) 63 (21.3)
Highest quintile 272 (19.8) 225 (20.9) 49 (16.6)
Marital status
Not married 403 (29.3) 321 (29.8) 82 (27.7)
Married 946 (68.8) 739 (68.5) 207 (69.9)
Marital status unknown 26 (1.9) 19 (1.8) 7 (2.4)
Comorbidity scores
0 776 (56.4) 615 (57) 161 (54.4)
1 405 (29.5) 315 (29.2) 90 (30.4)
2 194 (14.1) 149 (13.8) 45 (15.2)
Tumor location
Frontal lobe 286 (20.8) 234 (21.7) 52 (17.6)
Temporal lobe 377 (27.4) 334 (31.0) 43 (14.5)
Parietal lobe 249 (18.1) 180 (16.7) 69 (23.3)
Occipital lobe 92 (6.7) 77 (7.1) 15 (5.1)
Ventricle, brainstem, or
cerebellum
14 (1.0) 8 (0.8) 6 (2.1)
Involvement of two lobes or
bihemispheres
273 (19.9) 202 (18.7) 71 (24.0)
Brain location not speciﬁed (NOS) 84 (6.1) 44 (4.1) 40 (13.5)
Tumor size (mm)
, 30 237 (17.2) 170 (15.8) 67 (22.6)
30–41 193 (14.0) 151 (14.0) 42 (14.2)
42–53 231 (16.8) 201 (18.6) 30 (10.1)
 54 224 (16.3) 192 (17.8) 32 (10.8)
Size unknown 490 (35.6) 365 (33.8) 125 (42.2)
Weeks from surgery to initiation of radiation
Within 1 week 142 (10.3) 61 (5.7) 81 (27.4)
1–2 weeks 439 (31.9) 322 (29.4) 117 (39.5)
2–3 weeks 394 (28.7) 341 (31.6) 53 (17.9)
3–4 weeks 190 (13.8) 177 (16.4) 13 (4.4)
4–5 weeks 117 (8.5) 102 (9.5) 15 (5.1)
Continued
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likely to start radiotherapy at a later time. Moreover,
previous studies also supported that having tumor resec-
tion was a favorable prognostic factor for GBM.
4,14
Therefore, we anticipated that the type of surgery
would be a strong confounding factor for the variable
time from surgery to radiation, and because residual
confounding might be an issue even after statistical
adjustment, it was necessary to separate the analyses
into patients who had biopsies versusthose who received
surgical resections.
Of those who had tumor resections, the univariate
analysis revealed that beginning radiation after 22 days
post craniotomy had a protective effect (hazard ratio
[HR] ¼ 0.82, 95% CI 0.70–0.97) on survival. In multi-
variable analyses, the variable time interval to radiation
was no longer a signiﬁcant prognostic factor (Table 3).
The highest socioeconomic group, gross total resection,
and the administration of chemotherapy were signiﬁcant
favorable factors, whereas age 70 was a poor determi-
nant of survival. Subgroup analyses of patients with
gross total and subtotal resections also did not show
any association between the time interval from surgery
to radiation and overall survival. However, those with
gross total resection followed by cranial radiation after
22 days had a nonsigniﬁcant trend toward an improved
survival (HR ¼ 0.98, 95% CI 0.97–1.00, p ¼ 0.08).
This survival trend was not observed in those who
had subtotal resection and subsequently initiated radio-
therapy after 22 days (HR ¼ 0.86, 95% CI 0.67–1.10,
p ¼ 0.23).
To test the robustness of our ﬁndings, we repeated the
multivariate analysis of those with surgical resections
using the 25th to 75th percentiles of the variable time
interval from surgery to radiation as the reference,
which corresponded to 13–22 days. Initiation of radi-
ation .22 days post-surgery was not a signiﬁcant
factor for prognosis (HR ¼ 0.99, 95% CI 0.96–1.01,
p ¼ 0.13), and the time interval from 0 to 12 days
between surgery and radiation did not carry any
impact on survival (HR ¼ 1.07, 95% CI 0.92–1.25,
p ¼ 0.46). Moreover, as a sensitivity analysis, we
excluded subjects who died within 30 days of diagnosis
(instead of 90 days), but the conclusions remained the
same for both surgical groups (data not shown).
In testing the PH assumption, the variable chemother-
apyshowedasigniﬁcantdeviation(r ¼ 0.096,x
2 ¼ 9.78,
df ¼ 1, p ¼ 0.0018). This implied that the HR associated
with chemotherapeutic use was changing through time.
Since patients might have received chemotherapies more
frequently during the latter period of the study cohort,
and more effective therapy might have been prescribed
as the study period advanced, statistical violation of the
PH assumption by chemotherapy could have clinical cor-
relates. Thus, we ﬁtted a time-varying covariate, which
took into account the natural log of time, to accompany
the variable chemotherapy. The ﬁnal adjusted HR of che-
motherapy showed a signiﬁcant 9% improvement in the
overall survival (Table 3).
Of those who only had biopsies, radiation timing did
not have an impact on overall survival in the univariate
or multivariate analyses (Table 3). However, our sample
size is small (n ¼ 296), and the 95th percentile of
patients had already started radiation at day 37 post-
operatively. In the ﬁnal multivariate analysis, the
receipt of chemotherapy and higher socio-economic
classes (compared with the lowest group) were signiﬁ-
cant protective factors in those who only had biopsies.
Age group between 75 and 79 and African American
race were poor and borderline signiﬁcant risk factors.
Similar to those who had debulking surgery of their
tumors, the variable chemotherapy violated the PH
assumption; therefore, a time-varying covariate was
ﬁtted to the model as before.
None of the a priori–declared interaction terms were
signiﬁcant factors in our modeling. Fig. 1A and B shows
the Kaplan–Meier survival estimates of patients who
had surgical resections and those who had biopsies,
respectively.
Discussion
This population-based study found that initiation of
cranial radiation within 6 weeks of surgery/biopsy had
an equivalent survival effect in elderly patients diag-
nosed with GBM. Nevertheless, our results can only be
generalized to those who began radiotherapy within 6
weeks of surgery, because the 95th percentile of our




Frequency (%) for the Entire
Cohort, n 5 1375
Frequency (%) for those with
Craniotomy, n 5 1079
Frequency (%) for those with
Biopsy, n 5 296
5–6 weeks 60 (4.4) 49 (4.5) 11 (3.7)
. 6 weeks 33 (2.4) 27 (2.5) 6 (2.0)
Types of surgery
Biopsy 296 (21.5) N/AN /A
Subtotal resection 485 (35.3)
Gross total resection 574 (41.8)
NOS 20 (1.5)
Administration of chemotherapy 370 (26.9) 307 (28.5) 63 (21.3)
NOS, natural oriﬁce surgery.
aPer SEER–Medicare regulation, counts with ,5 patients must be stated as “, 5” instead of the actual numbers.
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even though our inclusion criteria allowed a time inter-
val of up to 90 days.
Data from Do et al.
7 also suggested no relationship
between time interval from surgery to the start of
radiotherapy and overall survival (HR ¼ 1.00, 95% CI
0.99–1.01, p ¼ 0.79). The investigators examined 182
malignant glioma patients diagnosed between 1979
and 1995 in the greater Sydney, Australia region. Their
median time from surgery to the beginning of radiation
was 26 days. However, they excluded 31 patients who
had small tumors, had complete resections, and were
treated with radiosurgery; they also eliminated those
who had been treated with adjuvant chemotherapy.
Perhaps, the removal of better prognostic groups from
their data set also abolished an inverse survival trend
similar to what we observed in our subgroup of patients
with gross total resections.
While our results and others’ showed no statistically
signiﬁcant relationship between waiting time and overall
survival, a retrospective study conducted by the RTOG
found that adult GBM patients radiated .4 weeks
Table 2. The associations between clinical/demographic variables and time from surgery to cranial radiation
Clinical Variables
a Days from Surgery to Radiation, Median (IQR) Odds Ratio (OR) p-Value
Age at diagnosis
65–69 14 (11) Reference
70–74 15 (11) 1.25 (0.92–1.70) 0.15
75–79 14 (12) 1.08 (0.77–1.52) 0.66
80 or above 15 (12) 1.18 (0.77–1.82) 0.44
GBM histological subtypes
Classical GBM 15 (11) Reference
Giant cell GBM 13 (14) 0.80 (0.23–2.73) 0.72
Gliosarcoma 16 (10) 0.91 (0.41–2.00) 0.81
Racial groups
Caucasian 15 (11) Reference
African American 14 (13) 1.16 (0.52–2.59) 0.72
Hispanic 28 (21) 1.20 (0.28–5.14) 0.8
Other racial group 15 (15) 0.76 (0.40–1.43) 0.39
Socio-economic status
Lowest quintile 15 (13) Reference
Second quintile 14 (12) 1.10 (0.75–1.64) 0.62
Third quintile 15 (11) 1.11 (0.74–1.66) 0.63
Fourth quintile 15 (11) 0.97 (0.65–1.45) 0.88
Highest quintile 14 (11) 0.81 (0.54–1.21) 0.3
Residence
Metropolitan areas 14.5 (11) Reference
Nonmetropolitan areas 15 (11) 0.88 (0.56–1.38) 0.58
Marital status
Not married 15 (11) Reference
Married 15 (11) 1.13 (0.86–1.49) 0.37
Marital status unknown 17 (18) 1.44 (0.54–3.84) 0.47
Comorbidity scores
0 14.5 (10) Reference
1 15 (12) 1.10 (0.83–1.44) 0.51
2 15 (11) 0.89 (0.61–1.28) 0.52
Types of surgery
b
Biopsy 10 (10) Reference
Subtotal resection 16 (10) 4.55 (3.22–6.44) 0.0001
Gross total resection 16 (10) 3.95 (2.81–5.57) 0.0001
NOS 14 (4) 5.42 (2.03–14.47) 0.001
Chemotherapy
Not given 15 (12) Reference
Given 14 (11) 0.81 (0.61–1.08) 0.15
NOS, natural oriﬁce surgery.
aResults were obtained from a multivariate logistic regression.
bIncreasing time interval from surgery to radiation is represented by OR .1.
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advantage over the group that started 2 weeks post-
operatively (HR ¼ 0.84, p , 0.0032).
6 Their results were
adjusted for age, performance status, extent of resection,
and recursive partitioning analysis class. As a retrospective
analysis, there might be unmeasured confounding factors
that accounted for the inverse relationship.
In contrast, another retrospective study of 172 malig-
nant glioma patients treated with radiotherapy in New
Zealand showed that every additional week of delay 2
weeks post operation increased the risk of death by
8.9% (95% CI 2.0%–16.1%).
5 Although these results
parallel the ﬁndings of other cancers that delay in radio-
therapy was associated with reduction in survival,
15,16
Table 3. Multivariable Cox proportional hazard analysis of the relationship between time from surgery to radiation and overall survival in
both patients who had surgical resections and those who only had biopsies
Clinical Variables HR (95% CI) for Surgical Resection, n 5 1,079 p-Value HR (95% CI) for Biopsy, n 5 296 p-Value
Time from surgery to radiation (days)
0–12 Reference Reference
13–16 1.00 (0.99–1.02) 0.65 0.87 (0.69–1.11)
a 0.27
17–22 1.00 (0.99–1.02) 0.9
23 and over 0.99 (0.97–1.01) 0.14
Age at diagnosis (years)
65–69 Reference Reference
70–74 1.27 (1.09–1.48) 0.002 1.06 (0.78–1.44) 0.72
75–79 1.29 (1.09–1.52) 0.004 1.37 (0.98–1.90) 0.06
80 or above 1.73 (1.39–2.16) 0.0001 1.16 (0.77–1.77) 0.48
GBM histological subtypes
Classical GBM Reference Reference
Giant cell GBM 0.89 (0.46–1.73) 0.73 0.55 (0.13–2.29) 0.41
Gliosarcoma 1.09 (0.76–1.57) 0.63 0.86 (0.12–6.36) 0.88
Racial groups
Caucasian Reference Reference
African American 0.85 (0.55–1.31) 0.47 1.72 (0.97–3.05) 0.06
Hispanic 0.73 (0.38–1.15) 0.1 1.43 (0.19–10.77) 0.73
Other racial group 0.77 (0.55–1.08) 0.13 1.21 (0.69–2.12) 0.5
Socio-economic status
Lowest quintile Reference Reference
Second quintile 0.96 (0.79–1.17) 0.69 0.43 (0.29–0.63) 0.0001
Third quintile 0.87 (0.71–1.07) 0.18 0.49 (0.33–0.71) 0.0001
Fourth quintile 0.83 (0.67–1.01) 0.059 0.32 (0.22–0.46) 0.0001
Highest quintile 0.79 (0.65–0.97) 0.023 0.34 (0.23–0.46) 0.0001
Residence
Metropolitan areas Reference Reference
Nonmetropolitan areas 0.88 (0.70–1.09) 0.25 1.02 (0.64–1.63) 0.94
Marital status
Not married Reference Reference
Married 0.99 (0.86–1.13) 0.83 1.00 (0.76–1.33) 0.98
Unknown 0.82 (0.51–1.32) 0.41 0.73 (0.34–1.62) 0.43
Comorbidity scores
0 Reference Reference
1 0.99 (0.86–1.13) 0.84 0.92 (0.63–1.36) 0.69
2 0.88 (0.73–1.05) 0.16 0.98 (0.69–1.39) 0.91
Types of surgery
Subtotal resection Reference N/A
Gross total resection 0.74 (0.65–0.86) 0.0001
NOS 0.81 (0.60–1.10) 0.97
Chemotherapy
Not given Reference Reference
Given 0.91 (0.86–0.97) 0.003 0.88 (0.82–0.94) 0.0001
aSince only 297 patients had biopsies, the variable time from surgery to radiation was dichotomized at its median at day 10. The group
.10 days was compared to the reference group 0–10 days.
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important differences that may partially explain the
opposite ﬁndings. First, because of resource constraints,
half of their patients initiated cranial radiation beyond 5
weeks and sometimes as late as 15 weeks post-
operatively. Therefore, it is possible that a prolonged
delay in starting radiotherapy is detrimental to survival
as suggested by these authors, but our study was
unable to verify this possibility as the wait experienced
by our cohort was brief in comparison. Moreover,
since a delay could be as long as 15 weeks, some patients
might have died prior to the completion of radiotherapy.
However, the paper did not seem to have excluded such
subjects. Their inclusion may confound the study,
because increased mortality could not be clearly attribu-
ted to delay in upfront radiation. In our analysis, we
excluded patients who died within 90 days of surgery.
Although this exclusion process had rendered our
study cohort “less representative” of the elderly GBM
population, it was a necessary step to ensure the validity
of our conclusion. Finally, chemotherapy was rarely pre-
scribed at recurrence in the New Zealand cohort and
thus there would be no potential compensation for sur-
vival associated with a late start in radiation.
Confounding factors that explained an inverse associ-
ation between waitingtime and survival inthe univariate
analysis are multiple and may reﬂect triaging physicians’
judgment to recommend early radiation for those judged
to have worse outcome and to defer radiation for
patients who were likely to have better prognoses.
Although such a complex decision could be difﬁcult to
account for adequately via regression analyses, some
factors that drove this decision include the extent of
residual disease after surgery, size of tumors, comorbid-
ities, post-operative complications, and Karnofsky per-
formance status (KPS) scores. The lack of information
on KPS scores in the SEER–Medicare linkage database
is a shortcoming, as a previous study showed that
those with higher KPS tended to begin radiotherapy
later.
5 However, this deﬁciency is at least partially
compensated for by subjects’ Charlson comorbidity
scores, which incorporated many key medical conditions
and symptoms, including hemiparesis and dementia.
Nevertheless, these scores are not perfect substitutes
for KPS in the assessment of brain tumor prognoses, as
unmeasured neurological deﬁcits such as gait imbalance,
visual ﬁeld deﬁcit, and neglect also have an impact on
the overall functioning of an individual. In other prog-
nostic studies of GBM, KPS is an important predictor
of survival.
17 Therefore, it may be a residual unmea-
sured confounding factor in our analysis.
Chemotherapy is an important confounding factor,
especially toward the later part of our study period
when chemotherapeutic agents were used more fre-
quently. However, we could estimate the prevalence of
only intravenous, but not oral, chemotherapy use in
this study, as temozolomide or other oral agents
cannot be captured as billed items in Medicare ﬁles.
During the late 1990s and early 2000, temozolomide
was used either at the time of recurrence or after
the completion of upfront cranial radiation.
18
Nevertheless, our ﬁnal result of 9% (resection group)
and 12% (biopsy group) improvement in the hazard of
dying due to chemotherapy was in accordance with
that obtained by a previous meta-analysis, which
showed a 15% reduction of mortality in GBM patients
treated with chemotherapy.
19 This meta-analysis did
not include the randomized trial that established the efﬁ-
cacy of concomitant temozolomide and radiation in
newly diagnosed GBM (the EORTC/NCIC trial).
20
Similarly, our study cohort was diagnosed prior to the
completion of this trial and thus confounding due to
this regimen would be kept to a minimum.
The EORTC/NCIC trial will likely diminish the
impact of short a delay in waiting time on the survival
of GBM. Although this study excluded patients aged
.70 years, and the worth of concomitant radiation
with temozolomide in the elderly is still debatable, this
combined therapy may add further beneﬁt to survival
if an elderly patient is able to tolerate it.
21,22 Therefore,
as this ﬁeld moves forward, more effective treatment
regimens may dilute the effects of a brief delay.
In summary, our results suggest that the initiation of
radiotherapy up to approximately 37 days after a biopsy
and 40 days following tumor resection will likely not
Fig. 1. (A) Kaplan–Meier survival curves of overall survival by time
interval from surgical resection to the initiation of radiotherapy. (B)
Kaplan–Meier curves of overall survival by time interval from
biopsy to the initiation of radiotherapy.
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for the inﬂuence of confounding factors. Effort should
be made to ensure the commencement of cranial radi-
ation at the earliest possible time after surgery/biopsy.
However, when delay is necessary, the aforementioned
upper limit of 6 weeks may serve as the latest time
point up to which radiotherapy could be started
without incurring an adverse effect on survival.
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